Trexquant Investment’s Xenon Pharmaceuticals XENE Stock Holding History

Trexquant Investment’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2M	Buy	202,455 +135,094	+201%	+$7.5M	0.07%	356
2026 Q1	$3.92M	Buy	+67,361	New	+$3.1M	0.03%	753
2025 Q1	–	Sell	-11,397	Closed	-$447K	–	1912
2024 Q4	$447K	Sell	11,397 -5,510	-33%	-$228K	0.01%	1314
2024 Q3	$666K	Sell	16,907 -23,940	-59%	-$965K	0.01%	1180
2024 Q2	$1.59M	Sell	40,847 -6,027	-13%	-$241K	0.02%	828
2024 Q1	$2.02M	Buy	+46,874	New	+$2.16M	0.04%	647
2023 Q3	–	Sell	-7,446	Closed	-$287K	–	1882
2023 Q2	$287K	Buy	+7,446	New	+$296K	0.01%	1212
2021 Q4	–	Sell	-23,213	Closed	-$355K	–	1668
2021 Q3	$355K	Buy	+23,213	New	+$403K	0.03%	670
2020 Q2	–	Sell	-31,793	Closed	-$361K	–	1538
2020 Q1	$361K	Buy	+31,793	New	+$453K	0.03%	781
2019 Q1	–	Sell	-30,810	Closed	-$194K	–	1361
2018 Q4	$194K	Buy	30,810 +19,612	+175%	+$174K	0.01%	922
2018 Q3	$148K	Buy	+11,198	New	+$130K	0.01%	866

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Trexquant Investment's XENE Position: Q2 2026 in Review

Trexquant Investment increased its Xenon Pharmaceuticals (XENE) stake by 201% in Q2 2026, buying an estimated $7.5M and bringing the position to 202,455 shares worth $12.2M. The position accounts for 0.07% of the portfolio, ranked #356.

Trexquant Investment first reported a position in XENE in Q3 2018 and has held it in 11 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Trexquant Investment held 202,455 shares of Xenon Pharmaceuticals worth $12.2M as of Q2 2026.
Trexquant Investment bought 135,094 Xenon Pharmaceuticals shares in Q2 2026, an estimated $7.5M.
Xenon Pharmaceuticals made up 0.07% of Trexquant Investment's portfolio in Q2 2026, its #356 holding.
Trexquant Investment first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 11 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.